HomeGeneticsConditionClopidogrel resistance
Back to Condition
Clopidogrel resistance
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Clopidogrel resistance

Clopidogrel resistance occurs when the antiplatelet drug clopidogrel is less effective than normal, increasing the risk of blood clots in certain patients.

Overview

Clopidogrel resistance is a condition where the drug clopidogrel (Plavix) does not work as effectively as expected. Clopidogrel is an antiplatelet drug used to prevent blood clots in individuals with a history of heart attack, stroke, deep vein thrombosis, or those who have received a stent to open blood vessels.

Risks and Complications

Patients with this resistance are at risk for serious complications because the drug fails to adequately prevent platelet aggregation. This can lead to:

  • Recurrent heart attacks or strokes
  • Thrombosis (blood clots) within stents, which impedes blood flow

Patients are categorized as intermediate metabolizers (receiving partial benefit) or poor metabolizers (receiving very limited benefit).

Causes

The condition is primarily linked to variations (polymorphisms) in the CYP2C19 gene. This gene provides instructions for an enzyme in the liver that converts clopidogrel into its active form. When the enzyme is nonfunctional—often due to the CYP2C19*2 or CYP2C19*3 polymorphisms—the drug cannot be activated to inhibit the P2RY12 receptor on platelets, allowing blood clots to form.

Inheritance

Clopidogrel resistance is inherited in a codominant manner. This means that both versions of the CYP2C19 gene are expressed and influence the trait. Individuals with one altered copy are typically intermediate metabolizers, while those with two altered copies are poor metabolizers. Not every individual with these gene variants will experience clinical resistance to the drug.

Frequently Asked Questions

Guidelines recommend switching to a more potent P2Y12 inhibitor that does not depend on CYP2C19 activation, such as ticagrelor or prasugrel (if no contraindications like prior stroke or high bleeding risk). Dose adjustments and bleeding risk assessment are essential before changing therapy.
Pre‑emptive testing is increasingly recommended for patients at high risk of poor response—those undergoing percutaneous coronary intervention, with a history of stroke/TIA, or of Asian ancestry where loss‑of‑function alleles are more common. Knowing the genotype upfront can guide the initial choice of antiplatelet therapy and avoid a trial‑and‑error approach.
Resistance is usually screened with platelet function tests such as VerifyNow P2Y12 assay, light transmission aggregometry, or vasodilator‑stimulated phosphoprotein (VASP) phosphorylation. A high P2Y12 reaction unit (PRU) despite standard dosing suggests inadequate platelet inhibition and possible resistance.
Yes. Smoking induces CYP1A2, which can modestly increase clopidogrel activation, while certain foods (e.g., grapefruit) and proton‑pump inhibitors like omeprazole inhibit CYP2C19 and may reduce drug conversion. Counsel patients to avoid strong CYP2C19 inhibitors and discuss any over‑the‑counter medications or supplements they take.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab

Sök
Om ossVillkor och policyVanliga frågorKontakta oss